PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Free Report) and ImmunoPrecise Antibodies (NASDAQ:IPA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of […]
Brokerages predict that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will report $5.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The business is scheduled to report its next earnings results on Monday, January […]
Wall Street analysts expect PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) to post sales of $5.83 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $9.17 million. The firm is […]
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) announced its earnings results on Thursday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.31), MarketWatch Earnings reports. PHAS stock opened at $1.14 on Friday. The business has a 50 day simple moving average of $1.46 and a 200-day simple moving average […]